Study 4
Study 4
Study 4
How TRIKAFTA was studied
How TRIKAFTA was studied
How TRIKAFTA was studied
This study evaluated the safety and tolerability of TRIKAFTA in children with cystic fibrosis (CF) age 2 through 5 years (Study 4). Because the focus was safety and side effects, the study did not use a placebo. The efficacy and safety of TRIKAFTA were evaluated in 2 studies of people with CF age 12 years and older, Study 1 and Study 2.
This study evaluated the safety and tolerability of TRIKAFTA in children with cystic fibrosis (CF) age 2 through 5 years (Study 4). Because the focus was safety and side effects, the study did not use a placebo. The efficacy and safety of TRIKAFTA were evaluated in 2 studies of people with CF age 12 years and older, Study 1 and Study 2.
This study evaluated the safety and tolerability of TRIKAFTA in children with cystic fibrosis (CF) age 2 through 5 years (Study 4). Because the focus was safety and side effects, the study did not use a placebo. The efficacy and safety of TRIKAFTA were evaluated in 2 studies of people with CF age 12 years and older, Study 1 and Study 2.
This study also evaluated:
Sweat chloride, which is a measure of the amount of salt in a person’s sweat. Sweat chloride level measurement is used to help diagnose CF. High sweat chloride levels are a hallmark of CF and are connected to the way CF works in the body.
Body mass index, which is a measure of someone’s weight in relation to their height.
75 children with CF age 2 through 5 years with either one copy of the F508del mutation and a mutation defined in the study* or two copies of the F508del mutation participated in the 24-week safety study.
Each child took TRIKAFTA granules every 12 hours with fat-containing food for 24 weeks (~6 months).
All participants knew they were taking TRIKAFTA, and no children in the study took placebo.
Each participant's dose of TRIKAFTA granules was based on their weight.
Learn about the recommended dose.
All participants continued to take their other prescribed CF therapies.
*Mutations that either do not make a CFTR protein or make a protein that is not responsive to ivacaftor and tezacaftor/ivacaftor.
*Mutations that either do not make a CFTR protein or make a protein that is not responsive to ivacaftor and tezacaftor/ivacaftor.
*Mutations that either do not make a CFTR protein or make a protein that is not responsive to ivacaftor and tezacaftor/ivacaftor.
What Should I Keep in Mind About the Study?
Because no one took placebo in the safety study, it is not known if changes seen in the study were due to TRIKAFTA.
Keep in mind that all results shown are an average of all people studied and differed among individuals and mutations. Your loved one may have a different experience.
This study took place during the COVID-19 pandemic. As a result, Vertex put in place certain processes and guidelines during the study, which may have affected the study results. Talk to your healthcare provider if you have any questions.
Results
Results
Results
What Were the Safety Results?
For children with CF age 2-5 years, the safety of TRIKAFTA observed in this study (Study 4) was similar to what was observed in people with CF age 12 years and older (Study 1).
Please see Important Safety Information.
What Else Was Found in the Study?
Sweat chloride decreased by 57.9 mmol/L on average through 24 weeks. On average, children started the study with a sweat chloride level of 100.7 mmol/L.
Body mass index (BMI) increased by 0.03 kg/m2 on average at 24 weeks. For example, a child who is 3’2’’ and weighs 38 pounds would gain about an ounce at 24 weeks.
The BMI result is not included in the full Prescribing Information for TRIKAFTA.
The BMI result is not included in the full Prescribing Information for TRIKAFTA.
The BMI result is not included in the full Prescribing Information for TRIKAFTA.
Keep Learning
About TRIKAFTA
About TRIKAFTA
About TRIKAFTA
Clayton, age 5
F508del/G542X
What is TRIKAFTA® (elexacaftor/tezacaftor/
ivacaftor and ivacaftor)?TRIKAFTA is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or another mutation that is responsive to treatment with TRIKAFTA.
Talk to your doctor to learn if you have an indicated CF gene mutation.
It is not known if TRIKAFTA is safe and effective in children under 2 years of age.
IMPORTANT SAFETY INFORMATION
Before taking TRIKAFTA, tell your doctor about all of your medical conditions, including if you:
- are allergic to TRIKAFTA or any ingredients in TRIKAFTA. See the Patient Information for a list of ingredients
- have kidney problems
- have or have had liver problems
- are pregnant or plan to become pregnant. It is not known if TRIKAFTA will harm your unborn baby. You and your doctor should decide if you will take TRIKAFTA while you are pregnant
- are breastfeeding or planning to breastfeed. It is not known if TRIKAFTA passes into your breast milk. You and your doctor should decide if you will take TRIKAFTA while you are breastfeeding
What is TRIKAFTA® (elexacaftor/tezacaftor/
ivacaftor and ivacaftor)?TRIKAFTA is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or another mutation that is responsive to treatment with TRIKAFTA.
Talk to your doctor to learn if you have an indicated CF gene mutation.
It is not known if TRIKAFTA is safe and effective in children under 2 years of age.
IMPORTANT SAFETY INFORMATION
Before taking TRIKAFTA, tell your doctor about all of your medical conditions, including if you:
- are allergic to TRIKAFTA or any ingredients in TRIKAFTA. See the Patient Information for a list of ingredients
- have kidney problems
- have or have had liver problems
- are pregnant or plan to become pregnant. It is not known if TRIKAFTA will harm your unborn baby. You and your doctor should decide if you will take TRIKAFTA while you are pregnant
- are breastfeeding or planning to breastfeed. It is not known if TRIKAFTA passes into your breast milk. You and your doctor should decide if you will take TRIKAFTA while you are breastfeeding